Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Rojo

Showing results (121-130 of 146) with videos related to

Pageof 15
Sort By:
The Pediatric Infectious Disease Journal|November 19, 2019
Growth Patterns in Children With Congenital Cytomegalovirus InfectionAlfredo Tagarro, Ruth Del Valle, Sara Dominguez-Rodríguez, et al.
Open Forum Infectious Diseases|June 3, 2026
Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized TrialHilda Angela Mujuru, Ellen White, Adeodata R Kekitiinwa, et al.
The Lancet. HIV|September 2, 2022
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trialPauline Amuge, Abbas Lugemwa, Ben Wynne, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|May 19, 2005
[Recommendations of the CEVIHP/SEIP/AEP/PNS on antiretroviral treatment in HIV-infected children and teenagers]José Tomás Ramos, María Isabel de José, Rosa Polo, et al.
The Pediatric Infectious Disease Journal|November 16, 2017
Congenital Cytomegalovirus: A European Expert Consensus Statement on Diagnosis and ManagementSuzanne E Luck, Jantien W Wieringa, Daniel Blázquez-Gamero, et al.
The Lancet. Child & Adolescent Health|January 24, 2026
Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trialAnna Turkova, Ellen White, Avy Violari, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 26, 2020
Multi-inflammatory Syndrome in Children Related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in SpainCinta Moraleda, Miquel Serna-Pascual, Antoni Soriano-Arandes, et al.
The Lancet. HIV|July 26, 2024
Analytical treatment interruption in children living with HIV: position statement from the EPIICAL consortiumLouise Kuhn, Shaun Barnabas, Nicola Cotugno, et al.
Journal of the Pediatric Infectious Diseases Society|October 16, 2023
First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe PneumoniaChishala Chabala, Tom G Jacobs, Cinta Moraleda, et al.
The Lancet. Child & Adolescent Health|August 10, 2023
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trialAnna Turkova, Ellen White, Adeodata R Kekitiinwa, et al.
Pageof 15

Showing results (121-130 of 146) with videos related to

Sort By:
Pageof 15
The Pediatric Infectious Disease Journal|November 19, 2019
Growth Patterns in Children With Congenital Cytomegalovirus InfectionAlfredo Tagarro, Ruth Del Valle, Sara Dominguez-Rodríguez, et al.
Open Forum Infectious Diseases|June 3, 2026
Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized TrialHilda Angela Mujuru, Ellen White, Adeodata R Kekitiinwa, et al.
The Lancet. HIV|September 2, 2022
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trialPauline Amuge, Abbas Lugemwa, Ben Wynne, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|May 19, 2005
[Recommendations of the CEVIHP/SEIP/AEP/PNS on antiretroviral treatment in HIV-infected children and teenagers]José Tomás Ramos, María Isabel de José, Rosa Polo, et al.
The Pediatric Infectious Disease Journal|November 16, 2017
Congenital Cytomegalovirus: A European Expert Consensus Statement on Diagnosis and ManagementSuzanne E Luck, Jantien W Wieringa, Daniel Blázquez-Gamero, et al.
The Lancet. Child & Adolescent Health|January 24, 2026
Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trialAnna Turkova, Ellen White, Avy Violari, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 26, 2020
Multi-inflammatory Syndrome in Children Related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in SpainCinta Moraleda, Miquel Serna-Pascual, Antoni Soriano-Arandes, et al.
The Lancet. HIV|July 26, 2024
Analytical treatment interruption in children living with HIV: position statement from the EPIICAL consortiumLouise Kuhn, Shaun Barnabas, Nicola Cotugno, et al.
Journal of the Pediatric Infectious Diseases Society|October 16, 2023
First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe PneumoniaChishala Chabala, Tom G Jacobs, Cinta Moraleda, et al.
The Lancet. Child & Adolescent Health|August 10, 2023
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trialAnna Turkova, Ellen White, Adeodata R Kekitiinwa, et al.
Pageof 15